Skip to main content
. 2022 Sep 23;13:933241. doi: 10.3389/fimmu.2022.933241

Figure 5.

Figure 5

Direct comparison of immune checkpoint blockades’ efficacy in multiple immunotherapy cohorts. (A) Response rates between different cuproptosis signature groups in the PMID30753825 cohort. (B) Response rates between different cuproptosis signature groups in the GSE35640 cohort. (C–H) Response rates between different cuproptosis signature groups in the GSE126044, GSE111636, GSE173839, GSE135222, PMID30013197, and PMID26359337 cohorts, respectively.